Two pathways, one problem: what patients are actually choosing between

For most patients weighing this decision, the question arrives after an MRI: 'Do I actually need surgery, or is there a non-operative route that could achieve something similar?' That is the fork this article addresses.

Both pathways — an outpatient injection appointment and an operative cartilage procedure — target focal cartilage defects in the knee or hip. Neither is appropriate for end-stage joint disease, where a replacement or resurfacing is the more realistic option.

The injection route involves a single clinic visit. The surgical alternatives differ from each other: microfracture is a one-stage arthroscopic procedure, while ACI/MACI involves two separate theatre admissions with a laboratory processing stage in between.

The choice is not always binary. Clinical guidance suggests that imaging and defect characteristics — not patient preference alone — determine which pathway is appropriate; for some patients, injection is assessed first, with surgery held in reserve if the response is insufficient.

The sections that follow compare these options across procedure, recovery, outcomes, cost, and patient fit.

How each treatment works on damaged cartilage

The three approaches differ not just in where they are performed, but in what they ask the body to do at the defect site.

ChondroFiller works through acellular matrix-induced chondrogenesis. The collagen scaffold is placed into the cartilage defect under ultrasound guidance, where it polymerises within approximately 3–5 minutes. Rather than introducing new cells itself, it acts as a framework that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, which gradually infiltrate the scaffold and support the repair process from within. Crucially, the defect surface is not disturbed or debrided beforehand: the gel coats what is already there, working top-down over the existing cartilage surface.

Microfracture reverses that direction. The surgeon creates small perforations in the subchondral bone plate, releasing marrow-derived stem cells that clot over the defect. The resulting tissue is fibrocartilage — mechanically weaker than native hyaline cartilage and, in published comparative data, associated with declining long-term outcomes and a reoperation rate of up to 41%.

ACI/MACI takes a different approach again: transplanting the patient's own cultured chondrocytes directly into the defect, aiming for hyaline-like repair tissue. This cell-transplant mechanism is distinct from both scaffold-induced recruitment and bone stimulation — a difference in biology, not just logistics.

All three repair processes require biological integration time, but the pace differs. Clot-based filling via microfracture establishes quickly; scaffold infiltration and cell-based maturation take longer to consolidate, with the tissue quality trade-off significant for each.

What the appointment or operation actually involves

Procedurally, the gap between these pathways is wider than most patients expect before they look closely.

The injection appointment

ChondroFiller is delivered in a single outpatient clinic visit. There is no theatre booking, no anaesthetic consent form, and no overnight admission. Under real-time ultrasound guidance, the collagen scaffold is placed into the defect through a standard injection; it polymerises in situ within approximately 3–5 minutes. Most patients leave the clinic unaided within about one hour of arriving — no crutches, no wound dressing, no escort requirement.

Microfracture surgery

Microfracture follows a conventional surgical pathway. The patient is admitted to theatre, receives a general or regional anaesthetic, and the surgeon works through small arthroscopic portals to drill or perforate the subchondral bone. It is typically performed as a day case or with a one-night stay, depending on the facility and how the joint responds.

ACI/MACI — two separate operations

ACI/MACI involves two distinct surgical admissions, separated by several weeks. The first operation harvests healthy cartilage cells arthroscopically; those cells are then cultured in a laboratory. The second procedure — open or arthroscopic — implants the processed scaffold into the defect. Patients face two separate consent and anaesthetic episodes, and two periods of post-operative recovery. For those balancing work or caring responsibilities, the staging alone is a meaningful planning burden.

Recovery timelines and return to activity

Recovery demands diverge sharply once each procedure is complete, and for working-age patients the difference is often the deciding factor.

After a ChondroFiller injection, the principal restriction is avoiding sustained compressive loading — prolonged standing, stair-climbing, or heavy weight-bearing — for approximately two weeks. That window is not merely cautionary: a 2024 biomechanical in-vitro study found that the scaffold carries initial instability under load and, in that early phase, does not protect the opposing cartilage surface. Compliance matters. Outside that restriction, most patients resume normal daily activity without crutches or a formal rehabilitation programme during the same period.

Microfracture carries a considerably heavier early recovery burden. Non-weight-bearing on crutches for four to six weeks is standard, with return to sport typically four to six months post-operation, depending on defect size and the quality of the fibrocartilage fill.

ACI/MACI demands the longest recovery arc of the three. An extended non-weight-bearing phase follows the implantation surgery, and full return to sporting activity is generally not expected until nine to eighteen months post-implant.

For anyone with a physically demanding job, sole caring responsibilities, or time-sensitive commitments, the crutch phase and rehabilitation timeline attached to surgical pathways represent a substantial real-world planning burden — one that an injection pathway largely sidesteps, provided the two-week loading restriction is respected.

What the evidence shows on outcomes — and where the gaps are

In a controlled randomised multicentre study (n=23), ChondroFiller was compared directly with microfracture for focal knee cartilage defects. The ChondroFiller group showed significant IKDC score improvement at 3, 6, and 12 months; MRI confirmed good immediate defect filling and progressive cartilage maturation throughout, with no adverse events recorded. A formal statistical comparison between the two arms was not possible: six of the ten patients allocated to microfracture refused the surgery before the trial could generate cross-group data — a dropout pattern that is itself worth noting when considering how acceptable surgery feels to patients facing the choice.

A formal expert analysis of ChondroFiller liquid for articular cartilage regeneration, drawing on the broader published literature, maps the outcome contrasts in finer detail. ChondroFiller liquid produced approximately 30 IKDC points improvement, with a complication rate of approximately 0% and a reoperation rate of 3–8%. Microfracture shows variable and often declining long-term outcomes, with reoperation rates reaching up to 41% in published series. ACI/MACI delivers a comparable functional gain — approximately 30–35 IKDC points — but carries a complication rate of up to 17% and a reoperation rate of up to 37%, figures that reflect the inherent complexity of a two-stage operative procedure.

Beyond the knee, Mazek (2021) prospectively followed 26 adults with acetabular hip lesions larger than 2 cm². At 3–5 years, 17 of 21 evaluable patients achieved good or excellent arthroscopic results. Patients with pre-existing osteoarthritis graded Tönnis 2–3 fared poorly, underlining the role of baseline joint status in determining likely benefit.

Across published ChondroFiller evidence, 70–85% of treated patients achieve meaningful symptom relief at 3–5 years — a figure that holds across knee, hip, and small-joint applications, but one drawn from several heterogeneous publications rather than a single large randomised trial. No head-to-head RCT has yet compared the injection pathway with ACI/MACI; individual ChondroFiller studies remain small in sample size, and most follow-up does not extend beyond five years. Whether the gains seen at that horizon hold or erode over a decade is a question the current evidence base cannot yet answer.

Who suits each pathway — and what access actually costs

Candidacy criteria

ChondroFiller injection suits a broad patient population: there is no upper age ceiling in clinical practice, and the injection route covers defects up to approximately 12 cm², making it applicable across a wide range of presentations. The primary contraindication is advanced osteoarthritis — Kellgren-Lawrence grade III or IV in the knee, or Tönnis grade 2–3 in the hip — where published results are consistently poor.

Microfracture is best matched to smaller, contained defects of less than 2–4 cm², and its fibrocartilage repair degrades more readily in older patients. ACI/MACI is indicated for larger focal defects — typically above 2–4 cm² — in younger, active patients able to commit to the full two-stage operative pathway and extended rehabilitation.

Cost and access

ChondroFiller injection is available only through private practice in the UK. Guide costs range from approximately £3,000 for a single-box treatment to £8,000 for three boxes, each figure inclusive of consultation, ultrasound, product, and a six-week follow-up. Microfracture is available privately at approximately £4,500; ACI/MACI, when privately funded, can exceed £40,000.

The NHS access picture is asymmetric. ACI/MACI received NICE approval in 2017 and remains the only cell-based cartilage therapy available on the NHS for qualifying focal knee defects. ChondroFiller injection has no current NHS funding pathway. For patients who meet NHS criteria for ACI/MACI, the financial calculation differs substantially from those who do not — a difference worth raising explicitly at first consultation.

The practical decision rests on imaging findings, defect characteristics, and baseline joint status. A specialist with working familiarity across both injection and surgical cartilage pathways is best placed to weigh those factors against each other for any individual patient.